WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD) today announced that PPD training manager Georgina “George” Havers has been named a 2015 Emerging Training Leader by Training magazine. The recognition acknowledges the talents, accomplishments and leadership of professionals who have worked in the training industry for two to 10 years.
PPD designs, develops and deploys a wide-range of employee learning and performance programs to support biopharmaceutical clients in advancing their clinical research programs. The company offers ongoing training and development that engages employees for optimal performance, leverages technology, develops staff and measures outcomes.
“George is a terrific example of the talented team ensuring that PPD employees nurture and grow the professional skills needed to help our clients succeed in today’s complex drug discovery and development landscape,” said Mike Wilkinson, executive vice president and chief information officer for PPD. “Congratulations to George. She is certainly worthy of this outstanding recognition.”
PPD’s programs for employee learning and development have won multiple awards for excellence and innovation. For the fourth consecutive year, PPD was named to Training magazine’s Training Top 125 list, honoring companies that demonstrate measurable results from effective employee training tied to strategic goals. PPD also has been recognized by the American Society for Training & Development, and the company earned a Skillsoft Perspectives Innovation Award for Empowering Learning Cultures in the Enterprise.
The successful nomination submission for Havers noted her exceptional “can-do” attitude and prolific work ethic. She led the learning component for revisions to PPD’s clinical foundation program that has prepared thousands of PPD’s clinical research associates (CRAs) to successfully monitor clinical trials of promising medical treatments. Havers employed the latest thinking in design content and Lean Six Sigma skills to help develop new materials that were engaging, interactive and representative of the latest advances in the training industry.
As a 2015 Emerging Training Leader, Havers will be featured in the May/June 2015 issue of Training magazine and on its website. Havers also will receive her award in February 2016 at a special ceremony during the Training Conference and Expo in Orlando.
About PPD
PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 13,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD’s award-winning learning and development programs and training award recipient Georgina Havers, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate, retain and train key personnel; risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments; competition in the outsourcing industry; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; consolidation in the pharmaceutical and biotechnology industries; rapid technological advances that make our services or capabilities less competitive; the ability to control SG&A spending; compliance with drug development regulations; changes in the regulation of the drug development process; and actual operating performance. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.
